Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

Current Medical Research and Opinion

Volumn 21, Issue 11, 2005, Pages 1809-1817

  Bartorelli, Luisa ^a,h   Giraldi, C ^b   Saccardo, M ^c   Cammarata, S ^d   Bottini, G ^e   Fasanaro, A M ^f   Trequattrini, A ^g  

^a Geriatrics Unit   (Italy)

^b CAMPO DI MARTE HOSPITAL   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f CARDARELLI HOSPITAL   (Italy)

^g Mental Health Center   (Italy)

^h NONE   (Italy)

Author keywords

Alzheimer's disease; Antipsychotics; Benzodiazepines; Donepezil; Galantamine; Rivastigmine; Switching

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DISORIENTATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROLOGICAL COMPLICATION; OBSERVATION; POLYPHARMACY; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; SYNCOPE; TREATMENT OUTCOME; TREMOR; VISUAL HALLUCINATION; VOMITING;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MENTAL STATUS SCHEDULE; PHENYLCARBAMATES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 27944457858     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65655     Document Type: Article

References (31)

1. Bullock R, Hammond G. Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17(Suppl 3):S80-5
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42
3. Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Des 2004;10:231-51
4. Cummings J, Cole G. Alzheimer disease. JAMA 2002;287:2335-8
5. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999;12:307-23
6. Davidsson P, Blennow K, Andreasen N, et al. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 2001;300:157-60
7. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998;32:70-7
8. Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-47
9. Greig N, Utsuki T, Qian-sheng Y, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Cur Med Res Opin 2001:159-65
10. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70
11. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002;127:6-19
12. Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 1992;21:381-96
13. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-72
14. Tinklenberg J, Newkirk L, Thompson J, et al. Donepezil treatment of Alzheimer's disease patients in California clinical practice: one-year follow-up. Eur Neuropsychopharmacol 2001;11 (Suppl 3):S317-8
15. Ministero della Sanità. Dipartimento per la valutazione dei medicinali e la farmacovigilanza. Protocollo CRONOS. Protocollo di monitoraggio dei piani di trattamento farmacologico per la malattia di Alzheimer
16. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. APA Washington DC; 1994
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. Report of the NINDS-ADRDA Work Group. Neurology 1984;34:939-44
18. Folstein MR, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
19. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist 1970;10:20-30
20. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. Gerontologist 1969;9:179-86
21. Guy W. Clinical Global Impressions (GCI). In: ECDEU Assessment manual for psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch: Rockville, MD; 1976, pp. 218-22
22. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 1986;26:260-6
23. Cook RJ, Wei W. Selection effects in randomized trials with count data. Statist Med 2002;21:515-31
24. Auriacombe S, Pere J-J, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Cur Med Res Opin 2002;18:129-38
25. Perry EK, Perry RH, Blessed G. Changes in brain cholinesterase in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-7
26. Costa J, Anand R, Cutler N, et al. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer patients. Poc Am Psych Assoc 1999;NR:561
27. Greig N, Utsuki T, Yu Q-S, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001;17:1-7
28. Edwards KR, Goodman W, Khoury KN, et al. Rapid changeover from donepezil to rivastigmine well tolerated. J Am Geriatr Soc 2001;49:S91-2
29. Etemad B, Anand R, Hartman R. Behavioural and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: a 26-week follow-up. Ann Neurol 50;(Suppl 1):S44-5
30. Messina J, Koumaras J, Hartman R. Treatment with rivastigmine reduces the need for psychotropic medication in patients with Alzheimer's disease residing in long-term care facilities. Poster presented at the 3rd Annual International Meeting for the College of Psychiatric and Neurologic Pharmacists, Washington, DC, USA. 6-9 April 2000
31. Anxiolytic sedatives hypnotics and antipsychotics. In: Martindale: the complete drug reference. 33rd edn. London: Pharmaceutical Press; 2002, pp. 674-6